Literature DB >> 10404317

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group.

F J Schmitz1, J Verhoef, A C Fluit.   

Abstract

Macrolide, lincosamide and streptogramin (MLS) antibiotics are chemically distinct inhibitors of bacterial protein synthesis. Resistance to MLS antibiotics may be constitutive or inducible. The purpose of this study is to update our understanding of the prevalence of different forms of MLS resistance in Europe. The analysis of 3653 clinical pneumococcal, staphylococcal and enterococcal isolates exhibited an average percentage of 21.3% and 6.2% intermediate and high-level penicillin-resistant Streptococcus pneumoniae, 21.8% methicillin-resistant Staphylococcus aureus and 11% vancomycin-resistant Enterococcus faecium. Geographical differences in erythromycin and clindamycin resistance in isolates of S. pneumoniae and S. aureus strongly reflect geographical variations in susceptibility to penicillin and methicillin, respectively. A very narrow range of MICs was obtained with quinupristin/dalfopristin, with no S. pneumoniae, S. aureus and E. faecium isolate having an MIC of > 4 mg/L, indicating a possible role of quinupristin/dalfopristin in the treatment of infections by multi-resistant Gram-positive bacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404317     DOI: 10.1093/jac/43.6.783

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Structural alterations in the translational attenuator of constitutively expressed erm(A) genes in Staphylococcus aureus.

Authors:  F J Schmitz; J Petridou; N Astfalk; S Scheuring; K Köhrer; J Verhoef; A C Fluit; S Schwarz
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

5.  National surveillance of methicillin-resistant Staphylococcus aureus in Belgian hospitals indicates rapid diversification of epidemic clones.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Raf De Ryck; Ricardo de Mendonça; Sylvianne Rottiers; Raymond Vanhoof; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Pilot study to evaluate 3 hygiene protocols on the reduction of bacterial load on the hands of veterinary staff performing routine equine physical examinations.

Authors:  Josie L Traub-Dargatz; J Scott Weese; Joyce D Rousseau; Magdalena Dunowska; Paul S Morley; David A Dargatz
Journal:  Can Vet J       Date:  2006-07       Impact factor: 1.008

Review 7.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  A practical guide to the treatment of complicated skin and soft tissue infections.

Authors:  Horatio B Fung; Joanne Y Chang; Stephen Kuczynski
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective.

Authors:  Stephan Harbarth; Werner Albrich; Christian Brun-Buisson
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.